G
Guido Nicolò
Researcher at National Cancer Research Institute
Publications - 57
Citations - 2900
Guido Nicolò is an academic researcher from National Cancer Research Institute. The author has contributed to research in topics: Sentinel lymph node & Breast cancer. The author has an hindex of 29, co-authored 57 publications receiving 2813 citations. Previous affiliations of Guido Nicolò include European Institute of Oncology.
Papers
More filters
Journal ArticleDOI
Correlation between steroid hormone receptors and prognostic factors in human breast cancer.
TL;DR: The significance of PgR versus ER status and the possible prognostic role of these receptors are investigated and the positivity of ER and PGR is correlated with patients' age at diagnosis, tumor size and relative grade.
Journal Article
Predictive value of some clinical and pathological parameters on upper level axillary lymph node involvement in breast cancer.
Salvatore Toma,F. Leonessa,A Romanini,F. Badellino,Stefano Bonassi,Guido Nicolò,Riccardo Rosso +6 more
TL;DR: It is concluded that, at present, a selection of possible candidates for a less than radical axillary dissection is not as yet feasible since the risk for III level invasion cannot be sufficiently defined.
Journal ArticleDOI
Differential nuclear matrix-intermediate filament expression in human prostate cancer in respect to benign prostatic hyperplasia
Ingles Alberti,Silvio Parodi,Paola Barboro,Paola Sanna,Guido Nicolò,C. Allera,Eligio Patrone,Stefano Galli,Cecilia Balbi +8 more
TL;DR: In this article, the changes in composition of the nuclear matrix-intermediate filament complex (NM-IF) isolated from prostate cancer (PCa), compared with benign prostatic hyperplasia (BPH), have been identified.
Journal ArticleDOI
Evaluation of Cathepsin D as Prognostic Predictor in Breast Cancer
Gian Paolo Barbi,Edoardo Margallo,Marco Margiocco,Michela Paganuzzi,Paola Marroni,Bruno Costanzi,Beatrice Gatteschi,Giorgio Tanara,Bruno Spina,Guido Nicolò +9 more
TL;DR: It is concluded that cathepsin D may be a useful prognostic predictor in breast cancer and further investigations are required to improve and extend the applications of this assay.
Journal ArticleDOI
Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial.
Silvia Bruno,Rosalba Torrisi,Massimo Costantini,Laura Baglietto,Vincenzo Fontana,Beatrice Gatteschi,Giovanni Melioli,Guido Nicolò,Antonio Curotto,Bruno Malcangi,Gian Paolo Bruttini,Marco Varaldo,Paolo Bruzzi,Andrea Decensi +13 more
TL;DR: It is concluded that DNA flow cytometry and conventional cytology on epithelial cells obtained from bladder washings do not appear to provide suitable surrogate endpoint biomarkers during the early stages of bladder carcinogenesis.